The study reveals that Novavax’s updated XBB.1.5 vaccine effectively induces cross-neutralizing antibodies against multiple Omicron XBB sub-variants in both mice and non-human primates.
Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation
The Food and Drug Administration on Wednesday approved a new treatment for people with non-small cell lung cancer that contains a rare genetic alteration called
November 16, 2023